CD36 and hepatocellular carcinoma: CD36+ CAFs in hepatocellular carcinoma (HCC) exhibit upregulated lipid metabolism-driven immunosuppression by impairing cytotoxic T lymphocyte activity and elevating PD-1 expression, as demonstrated in murine models (36).